Intramuscular injection, intravenous infusion, and intravenous bolus of oxytocin in the third stage of labor for prevention of postpartum hemorrhage: a three-arm randomized control trial.

BACKGROUND: Oxytocin for postpartum hemorrhage (PPH) prophylaxis is commonly administered by either intramuscular (IM) injection or intravenous (IV) infusion with both routes recommended equally and little discussion of potential differences between the two. This trial assesses the effectiveness and safety of 10 IU oxytocin administered as IM injection versus IV infusion and IV bolus during the third stage of labor for PPH prophylaxis. METHODS: In two tertiary level Egyptian maternity hospitals, women delivering vaginally without exposure to pre-delivery uterotonics were randomized to one of three prophylactic oxytocin administration groups after delivery of the baby. Blood loss was measured 1 h after delivery, and side effects were recorded. Primary outcomes were mean postpartum blood loss and proportion of women with postpartum blood loss ≥500 ml in this open-label, three-arm, parallel, randomized controlled trial. RESULTS: Four thousand nine hundred thirteen eligible, consenting women were randomized. Compared to IM injection, mean blood loss was 5.9% less in the IV infusion arm (95% CI: -8.5, - 3.3) and 11.1% less in the IV bolus arm (95% CI: -14.7, - 7.8). Risk of postpartum blood loss ≥500 ml in the IV infusion arm was significantly less compared to IM injection (0.8% vs. 1.5%, RR = 0.50, 95% CI: 0.27, 0.91). No side effects were reported in any arm. CONCLUSIONS: Intravenous oxytocin is more effective than intramuscular injection for the prevention of PPH in the third stage of labor. Oxytocin delivered by IV bolus presents no safety concerns after vaginal delivery and should be considered a safe option for PPH prophylaxis. TRIAL REGISTRATION: clinicaltrials.gov # NCT01914419 , posted August 2, 2013.

CA125, progesterone & ß-hCG in prediction of first trimester abortion / CA125, progesterona e ß-hCG na previsão de aborto no primeiro trimestre

Introduction: Pregnancy loss is a common medical problem in reproductive-age as more than fifty percent of human pregnancies are aborted before term. The majority are unrecognized occurring before or with the expected next menses. About 10­12 percent of all clinically diagnosed pregnancies are lost as first-trimester or early second trimester. The rate of fetal death after 14 weeks' gestation is much lower than the rate of pre-embryonic and embryonic loss. CA125 is a member of the mucin family glycoproteins. CA125 has found application as a tumor marker or biomarker that its level may be increased in the serum of some patients with specific types of cancers. Some studies detected that the abortion risk is increased in pregnant women with higher CA125 levels. Progesterone belongs to the C21 group of progestogen. Its main source in humans is the corpus luteum. Human chorionic gonadotropin (HCG) is a glycoprotein produced by syncytiotrophoblast. Aim of the work: The aim of this study was to determine the effectiveness of measuring maternal serum -HCG, progesterone, CA125 in prediction of first trimester abortion. Patients: The study included 90 pregnant women attending the ANC clinic in El-Shatby Maternity University Hospital. Patients were divided equally into two groups: Group I: 45 women with threatened abortion, subdivided into 2 subgroups: Subgroup A ­ Cases ended in abortion; Subgroup B ­ Cases continued as normal pregnancies. Group II: 45 pregnant women with normal pregnancy and were further subdivided into two subgroups: Subgroup C ­ Cases ended in abortion; Subgroup D ­ Cases continued as normal pregnancies. Exclusion criteria: (1) Multiple pregnancies; (2) Anembryonic pregnancy; (3) Pregnant women with prior treatment with progesterone; (4) History of endometriosis; (5) Fibromyoma with pregnancy. Methods: After clinical and sonographic examination, 3 mL venous blood have been taken once for estimation of serum level of -hCG, progesterone and CA125 by quantitative ELISA. Results: This is a case­control study. Out of the 90 pregnancies, 15 cases (16.6%) had aborted during follow-up, 9 cases (60%) of them had history of threatened abortion while 6 cases (40%) had no history of threatened abortion. Regarding Serum Progesterone level between studied groups, the calculated p value was <0.001. For Serum HCG, the calculated p value was <0.001. In Serum CA125 the calculated p value was <0.001.(AU)

Introdução: A perda da gravidez é problema clínico comum em mulheres em idade fértil, pois em mais de 50% das gestações humanas ocorre aborto antes do termo. Em sua maioria, tais abortos passam despercebidos; ocorrem antes da próxima menstruação ou juntamente com a próxima menstruação. Cerca de 10-12% de todos os abortos clinicamente diagnosticados ocorrem no primeiro trimestre ou no início do segundo trimestre. O percentual de mortes fetais após 14 semanas de gestação é muito mais baixo do que o percentual de abortos pré-embrionários ou embrionários. Foi constatado que CA125 tem aplicação como marcador tumoral ou como biomarcador, pois seu nível pode aumentar no soro de alguns pacientes portadores de tipos específicos de neoplasias. CA125 é um membro da família das glicoproteínas mucinas. Alguns estudos observaram que o risco de aborto aumenta em gestantes com níveis mais elevados de CA125. Progesterona pertence ao grupo C21 dos progestágenos. Em seres humanos, sua principal fonte é o corpo lúteo. Gonadotrofina coriônica humana (HCG) é uma glicoproteína produzida pelo sinciciotrofoblasto. Objetivo: Determinar a eficácia da determinação, no soro materno, de -HCG, progesterona e CA125 na previsão do aborto no primeiro trimestre. Pacientes: O estudo abrangeu 90 gestantes atendidas na clínica ANC na Maternidade do Hospital Universitário El-Shatby. As pacientes foram divididas equitativamente em dois grupos. Grupo I: 45 gestantes com ameaça de aborto, subdivididas em dois subgrupos: Subgrupo A ­ Casos que terminaram em aborto; Subgrupo B ­ Casos que tiveram continuidade como gestações normais. Grupo II: 45 gestantes com gestação normal, subdivididas em dois subgrupos: Subgrupo C ­ Casos que terminaram em aborto; Subgrupo D ­ Casos que tiveram continuidade como gestações normais. Critérios de exclusão: 1. Gestações múltiplas; 2. Gestação anembriônica; 3. Gestantes previamente tratadas com progesterona; 4. História de endometriose; 5. Fibromioma com gestação. Métodos: Após exame clínico e ultrassonográfico, 3 mL de sangue venoso foram coletados uma vez para estimar o nível sérico de -hCG, progesterona e CA125 por Elisa quantitativo. Resultados: Este é um estudo de casos-controle. Das 90 gestações, durante o seguimento ocorreram 15 (16,6%) casos de aborto; nove (60%) tinham história de ameaça de aborto, seis (40%) não tinham história de ameaça de aborto. Com relação ao nível sérico de progesterona entre os grupos estudados, calculamos p < 0,001. Para o nível sérico de CA125, calculamos p < 0,001.(AU)